New York, USA, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Crohn's Disease Treatment Drug Market is Expected to Showcase a Significant Growth During Study Period (2019–2032) | DelveInsight
The Crohn's disease market is expected to show positive growth, mainly attributed to the increased diagnosed prevalence and also, the launch of upcoming therapies during the forecast period (2023–2032).
DelveInsight’s Crohn's Disease Market Insights report includes a comprehensive understanding of current treatment practices, Crohn's disease emerging drugs, market share of individual therapies, and current and forecasted Crohn's disease market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
Key Takeaways from the Crohn's Disease Market Report
- According to DelveInsight's analysis, the market size for Crohn's disease reached USD 9 billion in 2022 across the 7MM and is expected to grow with a significant CAGR by 2032.
- DelveInsight's analysis reveals that the overall diagnosed prevalent population of Crohn's disease in the 7MM was reported as ~2 million in 2022. Within this, the diagnosed prevalent population of Crohn's disease patients in the United States specifically was identified to be 1 million in the same year.
- Prominent companies working in the domain of Crohn's disease, including AbbVie, Direct Biologics, LLC, Ossium Health, Inc., Pfizer, Bristol-Myers Squibb, Janssen Research & Development, LLC, Takeda, Prometheus Biosciences, Inc., Ventyx Biosciences, Inc, Telavant, Inc., Eli Lilly and Company, Boehringer Ingelheim, Agomab Therapeutics NV, Shire, Teva Branded Pharmaceutical Products R&D, Inc., Mesoblast, Inc., and other, are actively working on innovative drugs for Crohn's disease. These novel Crohn's disease therapies are anticipated to enter the Crohn's disease market in the forecast period and are expected to change the market.
- Some of the key therapies for Crohn's disease treatment include Risankizumab, ExoFlo, Ossium vBM-MSC, Etrasimod, Ozanimod, Guselkumab, Vedolizumab, PRA023 IV, VTX958, RVT-3101, Mirikizumab, BI 706321, AGMB-129, Ontamalimab, TEV-48574, Remestemcel-L, and others.
Discover which therapies are expected to grab the Crohn's disease market share @ Crohn's Disease Market Report
Crohn's Disease Overview
There are two primary forms of inflammatory bowel disease (IBD): ulcerative colitis and Crohn's disease. Ulcerative colitis is characterized by inflammation and ulcers along the surface of the large intestine and rectum. On the other hand, Crohn's disease involves inflammation in the digestive tract lining and may extend to deeper layers. While Crohn's disease is generally more severe than ulcerative colitis, it is slightly less prevalent. This condition can manifest at any age, but it is commonly diagnosed in individuals between 20 and 30 years old, with adolescents and adults being the most affected.
The exact reasons behind Crohn's disease remain unclear, though there's suspicion that genetics, immune response, and environmental factors play a role in its development. Symptoms of Crohn's disease can differ greatly among individuals, ranging from mild to severe. Typically, patients exhibit abdominal cramps, diarrhea, delayed growth, weight loss, fever, anemia, and possibly a mass in the lower right abdomen or perianal fistula. Beyond GI tract symptoms, some individuals might also encounter diverse symptoms affecting other parts of the body linked to Crohn's disease.
The identification of Crohn's disease necessitates a thorough examination involving a review of clinical history, physical examination, and additional diagnostic procedures. These may include tests for serological and fecal biomarkers, as well as cross-sectional and endoscopic imaging. Additionally, histological evaluation of biopsy specimens is essential for a comprehensive Crohn's disease diagnosis.
Crohn's Disease Epidemiology Segmentation
The Crohn's disease epidemiology section provides insights into the historical and current Crohn's disease patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.
The Crohn's disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Diagnosed Prevalent Cases of Crohn's Disease
- Age-specific Diagnosed Prevalent Cases of Crohn’s Disease
- Severity-specific Diagnosed Prevalent Cases of Crohn’s Disease
- Treated Cases of Crohn’s Disease
Download the report to understand which factors are driving Crohn's disease epidemiology trends @ Crohn's Disease Epidemiological Insights
Crohn's Disease Treatment Market
Therapeutic approaches for Crohn's disease encompass nutritional intervention, smoking cessation, and pharmacological treatment. In instances of severe or chronic active disease, surgery becomes a recommended option. Pharmacological therapy aims to alleviate symptoms, enhance or sustain quality of life, and minimize drug-related toxicity. Initial treatment commonly involves the use of glucocorticosteroids, with budesonide being the preferred first-line therapy. If contraindications arise with glucocorticosteroids, 5-aminosalicylate (5-ASA) is advised for patients. According to the European Crohn’s and Colitis Organization (ECCO), moderately active CD patients are typically administered azathioprine/6-mercaptopurine or methotrexate in conjunction with steroids. Glucocorticosteroids provide swift symptom relief and substantial inflammation reduction. However, due to potential long-term side effects, corticosteroids are reserved for managing flare-ups and are not employed for maintaining remission.
Biologic therapies for Crohn's disease treatment refer to antibodies designed to counteract specific proteins responsible for inducing inflammation. These therapies encompass anti-tumor necrosis factor and integrin blockers, which are endorsed by the National Institute for Health and Care Excellence and ECCO as a substitute treatment for individuals previously identified as steroid-refractory, dependent, or intolerant. In cases where standard medications prove ineffective, infliximab (Remicade) is prescribed to address moderate to severe Crohn’s disease. Additional anti-TNF agents, such as adalimumab (Humira) and adalimumab-atto (Amgevita), are utilized for Crohn’s disease. Vedolizumab (Entyvio), a biologic targeting integrin, provides an alternative to anti-TNF therapy for Crohn’s disease. Ustekinumab (Stelara) is another medication that inhibits IL-12 and IL-23.
Learn more about the FDA-approved drugs for Crohn's disease @ Drugs for Crohn's Disease Treatment
Key Crohn's Disease Therapies and Companies
- Risankizumab: AbbVie
- ExoFlo: Direct Biologics, LLC
- Ossium vBM-MSC: Ossium Health, Inc.
- Etrasimod: Pfizer
- Ozanimod: Bristol-Myers Squibb
- Guselkumab: Janssen Research & Development, LLC
- Vedolizumab: Takeda
- PRA023 IV: Prometheus Biosciences, Inc.
- VTX958: Ventyx Biosciences, Inc
- RVT-3101: Telavant, Inc.
- Mirikizumab: Eli Lilly and Company
- BI 706321: Boehringer Ingelheim
- AGMB-129: Agomab Therapeutics NV
- Ontamalimab: Shire
- TEV-48574: Teva Branded Pharmaceutical Products R&D, Inc.
- Remestemcel-L: Mesoblast, Inc.
To know more about Crohn's disease clinical trials, visit @ Crohn's Disease Treatment Drugs
Crohn's Disease Market Dynamics
The Crohn's Disease market dynamics are anticipated to change in the coming years. Various initiatives, led by both private and government organizations, aim to enhance awareness about the disease. Notably, World IBD Day officially marks Awareness Month, observed annually on May 19th. Researchers are actively engaged in identifying bacteria and viruses associated with Crohn's disease, paving the way for the development of targeted medications that manipulate these microbial factors to impede the disease's onset and progression. Given Crohn's disease's intricate pathophysiology, encompassing genomes, immune responses, diverse clinical manifestations, and treatment options, along with numerous parameters for monitoring and unpredictable complications, the field offers a substantial opportunity to implement the "precision medicine" concept in the treatment of IBD.
Furthermore, many potential therapies are being investigated for the treatment of Crohn's disease, and it is safe to predict that the treatment space will significantly impact the Crohn's disease market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the Crohn's disease market in the 7MM.
However, several factors may impede the growth of the Crohn's disease market.
Moreover, Crohn's disease treatment poses a significant economic burden and disrupts patients’ overall well-being and QOL. Furthermore, the Crohn's disease market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the Crohn's disease market growth.
| Crohn's Disease Report Metrics | Details |
| Study Period | 2019–2032 |
| Crohn's Disease Report Coverage | 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] |
| Crohn's Disease Market Size in 2022 | USD 9 Billion |
| Key Crohn's Disease Companies | AbbVie, Direct Biologics, LLC, Ossium Health, Inc., Pfizer, Bristol-Myers Squibb, Janssen Research & Development, LLC, Takeda, Prometheus Biosciences, Inc., Ventyx Biosciences, Inc, Telavant, Inc., Eli Lilly and Company, Boehringer Ingelheim, Agomab Therapeutics NV, Shire, Teva Branded Pharmaceutical Products R&D, Inc., Mesoblast, Inc., and others |
| Key Crohn's Disease Therapies | Risankizumab, ExoFlo, Ossium vBM-MSC, Etrasimod, Ozanimod, Guselkumab, Vedolizumab, PRA023 IV, VTX958, RVT-3101, Mirikizumab, BI 706321, AGMB-129, Ontamalimab, TEV-48574, Remestemcel-L, and others |
Scope of the Crohn's Disease Market Report
- Crohn's Disease Therapeutic Assessment: Crohn's Disease current marketed and emerging therapies
- Crohn's Disease Market Dynamics: Attribute Analysis of Emerging Crohn's Disease Drugs
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Crohn's Disease Market Access and Reimbursement
Discover more about Crohn's disease drugs in development @ Crohn's Disease Clinical Trials
Table of Contents
| 1. | Crohn's Disease Market Key Insights |
| 2. | Crohn's Disease Market Report Introduction |
| 3. | Crohn's Disease Market Overview at a Glance |
| 4. | Crohn's Disease Market Executive Summary |
| 5. | Disease Background and Overview |
| 6. | Crohn's Disease Treatment and Management |
| 7. | Crohn's Disease Epidemiology and Patient Population |
| 8. | Patient Journey |
| 9. | Crohn's Disease Marketed Drugs |
| 10. | Crohn's Disease Emerging Drugs |
| 11. | Seven Major Crohn's Disease Market Analysis |
| 12. | Crohn's Disease Market Outlook |
| 13. | Potential of Current and Emerging Therapies |
| 14. | KOL Views |
| 15. | Unmet Needs |
| 16. | SWOT Analysis |
| 17. | Appendix |
| 18. | DelveInsight Capabilities |
| 19. | Disclaimer |
| 20. | About DelveInsight |
Related Reports
Crohn's Disease Epidemiology Forecast
Crohn's Disease Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted Crohn's disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Crohn's Disease Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Crohn's disease companies, including Janssen, RedHill Biopharma, Amgen, Pfizer, Prometheus Biosciences, AgomAb Therapeutics, Hoffmann-La Roche, Gilead Sciences, Eli Lilly and Company, Celgene, AstraZeneca, Mesoblast, Alfasigma, Tiziana Life Sciences, Abivax, Arena Pharmaceuticals, Cytocom, HAV Vaccines Ltd, Enzo Biochem Inc., Stero Biotechs, Reistone Biopharma Company Limited, Qu Biologics, Pfizer, Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceuticals, Soligenix, Immunic, Pfizer, Atlantic Healthcare, 4D Pharma, Landos Biopharma, Janssen, Roche, Eisai, Bristol-Myers Squibb, Iltoo Pharma, Suzhou Connect Biopharmaceuticals, Theravance Biopharma, TaiwanJ Pharmaceuticals, Celularity, Cerecor, GlaxoSmithKline, KangStem Biotech, Immunic, Alpha Cancer Technologies, Koutif Therapeutics, Tract Therapeutics, Trio medicines, ChemoCentryx, Algernon Pharmaceuticals, Neuclone, JHL Biotech, Innovative Pharmacological Research (IPHAR) Co Ltd, Innovation Pharmaceuticals, Exeliom Biosciences SAS, AbbVie, Finch Therapeutics, Akeso Biopharma, Draconis Pharma, MakScientific, Engitix, Origo Biopharma, Navidea Biopharmaceuticals, Orchard Therapeutics, Xbrane, Thetis Pharmaceuticals, Temisis Therapeutics, Synedgen, Synlogic, Morphic Therapeutic, Metacrine, Curacle, Commence Bio Inc, Cloud Pharmaceuticals, Chong Kun Dang Pharmaceutical Corp, Avobis Bio LLC, Avexegen Therapeutics, Assembly Biosciences, Aibios Co Ltd, Aclaris Therapeutics, Athos Therapeutics, Denali Therapeutics, Educell doo, among others.
Irritable Bowel Syndrome Market
Irritable Bowel Syndrome Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key irritable bowel syndrome companies, including Arena Pharmaceuticals, 4D Pharma, NGM Biopharmaceuticals, OrphoMed, Boston Pharmaceuticals, RedHill Biopharma Limited, Takeda, Cosmo Technologies, CinRx Pharma, Rottapharm, Synthetic Biologics, Biomica, Metacrine, MGC Pharma, Napo Pharmaceuticals, Novome Biotechnologies, Renexxion, Sentia Medical Sciences, Serentrix LLC, Vitality Biopharma, among others.
Irritable Bowel Syndrome Pipeline
Irritable Bowel Syndrome Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key irritable bowel syndrome companies, including Arena Pharmaceuticals, 4D Pharma, OrphoMed, Boston Pharmaceuticals, RedHill Biopharma Limited, Takeda, Cosmo Technologies, CinRx Pharma, Rottapharm, Synthetic Biologics, Biomica, Metacrine, MGC Pharma, Napo Pharmaceuticals, Novome Biotechnologies, Renexxion, Sentia Medical Sciences, Serentrix LLC, Vitality Biopharma, among others.
Ulcerative Colitis Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key Ulcerative Colitis companies, including Eli Lilly and Company, Lipid Therapeutics, Hoffmann-La Roche, Arena Pharmaceuticals, InDex Pharmaceuticals, EA Pharma, Theravance Biopharma, Boehringer Ingelheim, Janssen Research & Development, Lycera, LG Chem, Iltoo Pharma, Immunic, Hutchison Medipharma, Tianjin Hemay Pharmaceutical, Celgene, among others.
Ulcerative Colitis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Ulcerative Colitis companies, including Eli Lilly and Company, Lipid Therapeutics, Hoffmann-La Roche, Arena Pharmaceuticals, InDex Pharmaceuticals, EA Pharma, Theravance Biopharma, Boehringer Ingelheim, Janssen Research & Development, Lycera, LG Chem, Iltoo Pharma, Immunic, Hutchison Medipharma, Tianjin Hemay Pharmaceutical, Celgene, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect with us on LinkedIn|Facebook|Twitter
